Gri bio continues to drive enrollment in ongoing phase 2a study of gri-0621 in idiopathic pulmonary fibrosis (“ipf”)

Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled  company on track to report interim biomarker data from the first 12 patients imminently completion of patient enrollment and topline results expected q3 2025 la jolla, ca, may 07, 2025 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (“nkt”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that enrollment for the 6 week interim analysis is complete with 24 of the 36 planned patients randomized in its ongoing phase 2a study evaluating gri-0621 for the treatment of idiopathic pulmonary fibrosis (“ipf”). “we are pleased with the progress made in this phase 2a biomarker study.
GRI Ratings Summary
GRI Quant Ranking